TOCA Tocagen Inc.

0.56
-0.01  -3%
Previous Close 0.58
Open 0.58
Price To Book 0.68
Market Cap 13,449,666
Shares 23,897,771
Volume 217,066
Short Ratio
Av. Daily Volume 659,108
Stock charts supplied by TradingView

NewsSee all news

  1. Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting

    SAN DIEGO, Nov. 22, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca

  2. Tocagen Reports Third Quarter 2019 Financial Results and Business Updates

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September

  3. Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting

    SAN DIEGO, Nov. 8, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Company presented data from the Toca 6 Phase 1b study of Toca 511 and

  4. Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12

    SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its third quarter 2019 financial results and business progress

  5. Tocagen Announces Restructuring to Focus on Clinical Development

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced a restructuring to focus its resources on the clinical development of Toca 511

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 primary and secondary endpoints missed - September 12, 2019.
Toca 511 & Toca FC - Toca 5
Recurrent brain cancer
Phase 1b at SITC 2019 noted median overall survival was 9.6 months.
Toca 511 (Toca 6)
Solid tumors
Phase 1 updated data at AACR April 3, 2019.
Toca 511 & Toca FC
Glioma
Phase 2/3 enrolment to commence late 2019.
Toca 511 & Toca FC - (NRG-BN006)
Glioblastoma (GBM)

Latest News

  1. Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting

    SAN DIEGO, Nov. 22, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca

  2. Tocagen Reports Third Quarter 2019 Financial Results and Business Updates

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September

  3. Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting

    SAN DIEGO, Nov. 8, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Company presented data from the Toca 6 Phase 1b study of Toca 511 and

  4. Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12

    SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its third quarter 2019 financial results and business progress

  5. Tocagen Announces Restructuring to Focus on Clinical Development

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced a restructuring to focus its resources on the clinical development of Toca 511

  6. Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer

    SAN DIEGO, Sept. 12, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating

  7. Tocagen to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced Marty Duvall, chief executive officer, will present and webcast at the Baird